Edition:
United States

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

1.05USD
14 Dec 2018
Change (% chg)

$0.03 (+2.94%)
Prev Close
$1.02
Open
$1.02
Day's High
$1.08
Day's Low
$1.02
Volume
27,274
Avg. Vol
47,848
52-wk High
$5.53
52-wk Low
$0.83

Latest Key Developments (Source: Significant Developments)

Fortress Biotech Q3 Loss Per Share $0.37
Friday, 9 Nov 2018 07:30am EST 

Nov 9 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.37.Q3 REVENUE $63.7 MILLION VERSUS $46.9 MILLION.  Full Article

Fortress Biotech Q2 Loss Per Share $0.50
Thursday, 9 Aug 2018 04:05pm EDT 

Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.50.Q2 REVENUE $63.8 MILLION VERSUS $50.7 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.  Full Article

Mustang Bio Q1 Loss Per Share $0.24
Monday, 14 May 2018 05:30pm EDT 

May 14 (Reuters) - Mustang Bio ::MUSTANG BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.MUSTANG BIO - Q1 LOSS PER SHARE $0.24.  Full Article

Fortress Biotech Reports FY Revenue Of $187.6 Mln
Friday, 16 Mar 2018 07:30am EDT 

March 16 (Reuters) - Fortress Biotech Inc ::FORTRESS BIOTECH REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.SAYS FY REVENUE $187.6 MILLION.‍AS OF DECEMBER 31, 2017, CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS, CASH DEPOSITS, RESTRICTED CASH TOTALED $168.3 MILLION​.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 08:00am EST 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Monday, 11 Dec 2017 04:30pm EST 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 08:30am EST 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article

Fortress Biotech posts Q3 loss per share $0.67
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Fortress Biotech Inc :Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.67.Q3 revenue $46.9 million versus $1.0 million.  Full Article

Fortress Biotech announces pricing of series a preferred stock offering
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Fortress Biotech Inc :Fortress Biotech Inc announces pricing of series a preferred stock offering.Fortress Biotech Inc - ‍priced offering of one million shares of its 9.375 pct series a cumulative redeemable perpetual preferred stock at $25.00 per share​.  Full Article

Fortress Biotech proposes public offering of Series A preferred stock
Wednesday, 1 Nov 2017 09:20am EDT 

Nov 1 (Reuters) - Fortress Biotech Inc :Fortress Biotech announces proposed public offering of Series A preferred stock.  Full Article

Fortress Bio to sell majority stake in brokerage National Holdings

Fortress Biotech Inc said on Monday it will sell its majority stake in the independent wealth management firm National Holdings Corp , bringing an end to an unusual ownership arrangement that had drawn scrutiny from the investing and securities industries.